Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

2010404 citationsJournal Article

Authors

Bradley J. Monk · Délégation Paris 5

Thomas J. Herzog · Délégation Paris 5

Stanley B. Kaye · Délégation Paris 5

Carolyn Krasner · Délégation Paris 5

Jan B. Vermorken · Délégation Paris 5

Franco M. Muggia · Délégation Paris 5

Éric Pujade-Lauraine ·

Abstract

When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

Topics & Keywords

Ovarian cancer diagnosis and treatment Colorectal and Anal Carcinomas Sarcoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 19, pp. 3107-3114

DOI: 10.1200/jco.2009.25.4037

Field-Weighted Citation Impact: 38.04